Fibrinolysis in Disease - The Malignant Process, Interventions in Thrombogenic Mechanisms, and Novel Treatment Modalities, Volume 2

Description

Fibrinolysis in Disease reviews the state of the art of basic and clinical aspects of the fibrinolytic enzyme system. The text, authored by outstanding and internationally known investigators, is presented in two books.

The Malignant Process, Interventions in Thrombogenic Mechanisms, and Novel Treatment Modalities discusses the molecular biology of the system's key components and their fundamental roles in a variety of thrombotic and metabolic disorders. Molecular and Hemovascular Aspects of Fybrinolysis presents the latest findings and concepts of the association between plasminogen activator (u-PA) overexpression and abnormal growth regulation in a variety of solid tumors and in leukemia. One chapter deals with various successful interventions in thrombogenic mechanisms, ranging from exercise and diet to anticoagulants and direct and indirect thrombolytic agents. It concludes with a projection of exciting, novel treatment modalities in thrombotic and malignant diseases.

Contents

of The Malignant Process:

The Role of the Plasminogen Activation System in Neoplasia

uPA Production, Receptor Display, and Differentiation, D. Boyd and M. Brattain

Interactions between Epidermal Growth Factor and Its Receptor in the Regulation of Urokinase Plasminogen Activator in Normal and Malignant Keratinocytes, M.J. Niedbala and A.C. Sartorelli

Tissue-Type and Urokinase-Type Plasminogen Activators as Prognostic Markers in Breast Cancer, M.J. Duffy, D. Reilly, P. O'Grady, N. Nolan, N. O'Higgins, J.J. Fennelly, and P.A. Andreasen

Both uPA and PAI-1 Are Independent Prognosticators of Relapse and Death in Breast Cancer, F. Jänicke, M. Schmitt, and H. Graeff

PAI-1 and PAI-2 Levels as Predictors in Staging Malignancy in Breast Cancer, K. Sumiyoshi, T. Urano, Y. Takada, and A. Takada

Plasminogen Activation in Ovarian Cancer, B. Casslén and B. Astedt

Increased Urokinase-Plasminogen Activator (u-PA) Expression Correlates with the Aggressive Phenotype in Human Prostate Cancer Cells, J.M. Kozlowski, H.N. Keer, F.D. Gaylis, and C. Lee

Epidermal Growth Factor Receptor and Plasminogen Activators in Bladder Cancer, D.J. Thomas and D.E. Neal

Role of u-PA in Determining the Biological Behavior of Gastric Cancer, S. Takai, M. Yamamura, S. Uetsuji, and M. Yamamoto

u-PA Levels in Plasma, Urine, and Tissues of Patients with Cancer of the Digestive Tract, N. Nishino, S. Baba, and A. Takada

u-PA:t-PA Ratio as Discriminator in Gastrointestinal Cancer, H.W. Verspaget

Plasminogen Activators in Osteoblastic Cells, L.C. Carpio and R. Dziak

u-PA as an Autocrine Mitogen in Human Melanoma Cells, B.R. Binder and M. Ruthner

PAI-1 and PAI-2 in Leukemic Patients, B. Bennett and A. Croll

Interventions

Exercise

Effects of Physical Training and Smoking Cessation on PAI Levels, J.-C. Gris and J.-F. Schved

Fibrinolytic Response to Strenuous Physical Exercise, J.-B. Hansen

Diet

Hyperlipidemia and Reduced Fibrinolysis-Diet or Drugs? P. Andersen

Effect of Fish Oil on Some Parameters of Fibrinolysis, O. Haglund, T.G.P. Saldeen, and J.L. Mehta

Diet and Fibrinolysis, with Special Reference to the Effects of Fiber Intake, T.K. Nilsson, K. Boman, J.-X. Zhang, and G. Hallmans

Direct Thrombolytic Agents

Conjunctive Thrombolytic and Antithrombotic Therapy for Acute Myocardial Infarction, H.J. Rapold

Platelet Activation During Thrombolytic Therapy in Unstable Angina, M. Reilly and D.J. Fitzgerald

Paradoxic Prothrombotic Effects During Pharmacologic Thrombolysis, G.A. Ewald and P.R. Eisenberg

Plasma Fibrinopeptide A and B Levels May Not Be Specific Markers of Thrombin Activity During Pharmacologic Thrombolysis, J.I. Weitz

Efficient Coronary Thrombolysis Is Dependent on Concentrations of Free t-PA, C.L. Lucore

Thrombolytic Therapy in Patients with Acute Massive Pulmonary Embolism, M. Verstraete

Thrombolysis in Cerebrovascular Ischemia, G.J. del Zoppo

Indirect Thrombolytic Agents

Use of Ancrod in Patients with Heparin-Induced Thrombocytopenia and During Cardiopulmonary Bypass Surgery, K. Aogaichi

Therapy with Ancrod in Acute Ischemic Stroke, D.E. Levy

Fibrinolytic and Clinical Effects of Ancrod in Systemic Lupus Erythematosus and Acute Ischemic Stroke, P. Glas-Greenwalt

Fibrinolytic Response to dDAVP and Its Potential Clinical Relevance, E. Törnebohm-Roche

Heparin and Others

Interaction of Heparin with Plasminogen Activators and Plasminogen In Vitro, D.C. Rijken, G.A.W. de Munk, and A.F.H. Jie

Profibrinolytic Effects of Modified Heparins, R. Porta and R. Pescador

Disease and Drug Modulation of Fibrinolysis, J. Fareed, P. Bacher, J.M. Walenga, D.A. Hoppensteadt, and E.W. Bermes

Future

Genetically Engineered New Thrombolytic Agents, H.R. Lijnen and D. Collen

Antibody Targeting of Plasminogen Activators, M.S. Runge, K.W. Harris, and C. Bode

The Potential Use of Anti-PAI-1 Antibodies as Adjuvants in Thrombolytic Therapy, M. Levi and B.J. Biemond

Vampire Bat Salivary Plasminogen Activator, S.J. Gardell

Stimulation of Indigenous Fibrinolysis: A Novel Approach of Prevention from Thrombosis, G. Dooijewaard and C. Kluft

The Potentials of Retinoids as Stimulators of Endogenous Tissue-Type Plasminogen Activator, T. Kooistra

Growth Factor Mechanisms and Cancer Therapy, K.R. Meehan and L.R. Zacharski

Related Subjects

1. Hematology
2. Cardiology and Cardiovascular Medicine
3. Hematology